Novel long non-coding RNA lncAMPC downregulates PTEN via miR-214 to promote nasopharyngeal carcinoma progression

被引:0
作者
Xianqing Li
Shunlin Ouyang
机构
[1] The Third Affiliated Hospital of Guangzhou Medical University,
来源
Molecular and Cellular Biochemistry | 2022年 / 477卷
关键词
LncAMPC; Nasopharyngeal carcinoma; PTEN; miR-214; Cell cycle;
D O I
暂无
中图分类号
学科分类号
摘要
Long non-coding RNAs (lncRNAs) are a type of non-coding RNAs with transcript lengths exceeding 200 nt. lncRNAs suppress or promote cancer mainly by regulating gene expression. The aim of this study was to explore the role of lncRNAs activated in metastatic PCa (lncAMPC) in nasopharyngeal carcinoma (NPC). Total RNAs were isolated from NPC and adjacent non-tumor tissues from 60 NPC patients and subjected to RT-qPCR to analyze differential expression of lncAMPC and miR-214. The roles of lncAMPC and miR-214 in regulating PTEN expression were analyzed using RT-qPCR and Western blot. Cell proliferation was analyzed using the BrdU assay. The results showed that lncAMPC was overexpressed in NPC tissues and was localized in both nuclei and cytoplasms of NPC cells. MiR-214 was positively correlated with lncAMPC. LncAMPC overexpression upregulated miR-214 and indirectly downregulated PTEN via miR-214. BrdU incorporation assay showed that lncAMPC and miR-214 overexpression increased cell proliferation. PTEN overexpression completely reversed the promoting effects of lncAMPC and miR-214 overexpression on cell proliferation. Therefore, lncAMPC might downregulate PTEN via miR-214 to increase NPC cell proliferation.
引用
收藏
页码:805 / 814
页数:9
相关论文
共 130 条
  • [1] Chua MLK(2016)Nasopharyngeal carcinoma Lancet 387 1012-1024
  • [2] Wee JTS(2018)Nasopharyngeal carcinoma: a review of current updates Exp Ther Med 15 3687-3692
  • [3] Hui EP(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 394-424
  • [4] Chan ATC(2019)Systematic review and meta-analysis of prognostic microRNA biomarkers for survival outcome in nasopharyngeal carcinoma PLoS ONE 14 1139-2209
  • [5] Wu L(2018)Long-term survival and late complications of intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma BMC Cancer 18 21-1757
  • [6] Li C(2016)Advances in systemic treatment for nasopharyngeal carcinoma Chin Clin Oncol 5 2185-433
  • [7] Pan L(2019)Management of locally recurrent nasopharyngeal carcinoma Cancer Treat Rev 79 1750-562
  • [8] Bray F(2019)Molecular targeted therapy in the management of recurrent and metastatic nasopharyngeal carcinoma: a comprehensive literature review Cureus 11 425-3501
  • [9] Ferlay J(2020)Anti-EGFR therapies in nasopharyngeal carcinoma Biomed Pharmacother 131 547-13459
  • [10] Soerjomataram I(2012)Nasopharyngeal carcinoma signaling pathway: an update on molecular biomarkers Int J Cell Biol 2012 338-229